

# Contents

Introduction to the BCSC . . . . .	xvii
<b>Objectives . . . . .</b>	<b>1</b>
<b>1 Social Determinants of Health . . . . .</b>	<b>3</b>
Highlights . . . . .	3
Introduction . . . . .	3
Categories of Social Determinants of Health . . . . .	5
Health Care System . . . . .	5
Economic Stability . . . . .	7
Education . . . . .	7
Neighborhood and Physical Environment . . . . .	8
Food . . . . .	8
Community and Social Context . . . . .	8
Discrimination and Social Determinants of Health . . . . .	8
Race and Ethnicity . . . . .	9
Sex and Gender . . . . .	9
Sexual Orientation and Gender Identity . . . . .	10
Age and Disability . . . . .	10
Approaches to Addressing Social Determinants of Health . . . . .	10
<b>2 Using Research to Improve Clinical Practice . . . . .</b>	<b>13</b>
Highlights . . . . .	13
Researching Answers to Clinical Questions . . . . .	13
Sources of Information . . . . .	13
Data Fundamentals . . . . .	14
Critical Reading of Studies . . . . .	15
Understanding Study Design . . . . .	20
Case Reports . . . . .	20
Case Series . . . . .	20
Case-Control Studies . . . . .	24
Cross-Sectional Studies . . . . .	24
Cohort Studies . . . . .	24
Clinical Trials . . . . .	26
Real-World Studies . . . . .	26
Systematic Reviews and Meta-analyses of Clinical Trials . . . . .	27
Interpreting Diagnostic and Screening Tests . . . . .	27
The Straightforward Case . . . . .	28
Complicating Features . . . . .	30
Summary . . . . .	34

Discussing Benefits, Risks, Probabilities, and Expected Outcomes With Patients . . . . .	34
Risk Differences and Probability. . . . .	34
Number Needed to Treat. . . . .	35
Odds Ratios . . . . .	35
Risk Calculators . . . . .	35
How to Measure and Improve Clinical Practice . . . . .	36
Using Big Data to Improve Clinical Practice . . . . .	36
Issues in Designing a Measurement System . . . . .	37
Implementation of a Monitoring System . . . . .	38
Analysis of the Results . . . . .	40
Methods of Presenting Data to Facilitate Continuous Improvement . . . . .	40
Other Features of Continuous Quality Improvement . . . . .	43
Evidence-Based Medicine . . . . .	43
Summary . . . . .	44
<b>3 Endocrine Disorders . . . . .</b>	<b>45</b>
Highlights . . . . .	45
Diabetes Mellitus . . . . .	45
Classification of Diabetes. . . . .	45
Diagnosis of Diabetes . . . . .	46
Reduction of Risk for Diabetes . . . . .	47
Treatment . . . . .	48
Complications of Diabetes . . . . .	50
Thyroid Disease . . . . .	53
Physiology . . . . .	53
Tests of Thyroid Function . . . . .	54
Hyperthyroidism . . . . .	55
Hypothyroidism . . . . .	56
Thyroiditis . . . . .	57
Thyroid Tumors . . . . .	58
Disorders of the Hypothalamic-Pituitary Axis . . . . .	58
Pituitary Adenomas . . . . .	59
Pituitary Apoplexy . . . . .	60
Multiple Endocrine Neoplasia Syndromes . . . . .	61
<b>4 Hypertension . . . . .</b>	<b>63</b>
Highlights . . . . .	63
Introduction . . . . .	63
Classification of Blood Pressure and Diagnosis of Hypertension. . . . .	64
Etiology and Pathogenesis of Hypertension. . . . .	65
Evaluation of Patients With Hypertension . . . . .	67
Treatment of Hypertension. . . . .	68
Lifestyle Modifications. . . . .	68
Pharmacologic Treatment . . . . .	68
Future Treatments and Targets for Hypertension. . . . .	75

Special Considerations . . . . .	76
Ischemic Heart Disease . . . . .	76
Heart Failure . . . . .	76
Diabetes and Hypertension . . . . .	76
Chronic Renal Disease . . . . .	77
Cerebrovascular Disease . . . . .	77
Obesity and Metabolic Syndrome . . . . .	77
Obstructive Sleep Apnea Syndrome . . . . .	77
Left Ventricular Hypertrophy . . . . .	77
Peripheral Arterial Disease . . . . .	78
Orthostatic Hypotension . . . . .	78
Hypertension in Older Patients . . . . .	78
Women and Pregnancy . . . . .	79
Children and Adolescents . . . . .	79
Withdrawal Syndromes . . . . .	80
Monoamine Oxidase Inhibitor Drug and Food Interactions . . . . .	80
Hypertensive Crisis . . . . .	80
<b>5 Hyperlipidemia and Cardiovascular Risk . . . . .</b>	<b>83</b>
Highlights . . . . .	83
Introduction . . . . .	83
Lipoproteins, Cholesterol, and Cardiovascular Disease . . . . .	84
Risk Assessment . . . . .	84
Management . . . . .	86
Lifestyle Modification . . . . .	86
The Role of Statins . . . . .	87
Other LDL-Lowering Drugs . . . . .	88
Metabolic Syndrome . . . . .	89
<b>6 Acquired Heart Disease . . . . .</b>	<b>93</b>
Highlights . . . . .	93
Ischemic Heart Disease . . . . .	93
Pathophysiology . . . . .	93
Risk Factors for Coronary Heart Disease . . . . .	94
Clinical Syndromes . . . . .	94
Noninvasive Cardiac Diagnostic Procedures . . . . .	98
Invasive Cardiac Diagnostic Procedures . . . . .	100
Management of Ischemic Heart Disease . . . . .	101
Congestive Heart Failure . . . . .	107
Classification . . . . .	107
Symptoms . . . . .	108
Clinical Signs . . . . .	108
Diagnostic Evaluation . . . . .	109
Etiology . . . . .	109
Medical and Nonsurgical Management . . . . .	110
Invasive or Surgical Management . . . . .	112

Disorders of Cardiac Rhythm . . . . .	112
Bradyarrhythmias and Conduction Disturbances . . . . .	113
Premature Contractions . . . . .	113
Tachyarrhythmias . . . . .	114
<b>7 Cerebrovascular Disease . . . . .</b>	<b>119</b>
Highlights . . . . .	119
Introduction . . . . .	119
Cerebral Ischemia . . . . .	120
Transient Cerebral Ischemia . . . . .	120
Ischemic Stroke . . . . .	120
Diagnosis and Assessment . . . . .	121
Management of Cerebral Ischemia . . . . .	123
Postacute Management . . . . .	124
Carotid Occlusive Disease . . . . .	125
Diagnostic Imaging for Carotid Stenosis . . . . .	125
Management of Carotid Stenosis . . . . .	126
Intracranial Hemorrhage . . . . .	130
Intracerebral Hemorrhage . . . . .	130
Intraventricular Hemorrhage . . . . .	130
Subarachnoid Hemorrhage . . . . .	131
<b>8 Pulmonary Diseases . . . . .</b>	<b>133</b>
Highlights . . . . .	133
Introduction . . . . .	133
Obstructive Lung Diseases . . . . .	133
Restrictive Lung Diseases . . . . .	135
Evaluation . . . . .	136
Treatment . . . . .	136
Nonpharmacologic Treatment . . . . .	136
Pharmacologic Treatment . . . . .	137
Pulmonary Aspects of COVID-19 . . . . .	139
<b>9 Hematologic Disorders . . . . .</b>	<b>141</b>
Highlights . . . . .	141
Blood Composition . . . . .	141
Erythropoiesis . . . . .	141
Anemia . . . . .	142
Anemia Due to Blood Loss or Nutritional Deficiency . . . . .	142
Anemia Due to Defective Hemoglobin Synthesis (Hemoglobinopathies) . . . . .	144
Anemia Due to Destruction of Red Blood Cells . . . . .	146
Anemia Due to Inflammation and Chronic Disease . . . . .	147
Anemia Due to Bone Marrow Disorders . . . . .	147
Disorders of Hemostasis . . . . .	148
Laboratory Evaluation of Hemostasis and Blood Coagulation . . . . .	149
Clinical Manifestations of Hemostatic Abnormalities . . . . .	150
Vascular Disorders . . . . .	150

Platelet Disorders . . . . .	151
Disorders of Blood Coagulation . . . . .	154
Primary Hypercoagulable States . . . . .	157
Secondary Hypercoagulable States . . . . .	159
<b>10 Rheumatic Disorders . . . . .</b>	<b>161</b>
Highlights . . . . .	161
Introduction . . . . .	161
Rheumatoid Arthritis . . . . .	161
Extra-articular Manifestations . . . . .	162
Laboratory Testing . . . . .	163
Treatment . . . . .	163
Spondyloarthritis . . . . .	164
Ankylosing Spondylitis . . . . .	164
Reactive Arthritis . . . . .	165
Enteropathic Arthritis . . . . .	165
Psoriatic Arthritis . . . . .	166
Juvenile Idiopathic Arthritis . . . . .	167
Systemic Lupus Erythematosus . . . . .	168
Clinical Findings . . . . .	168
Diagnosis . . . . .	170
Treatment . . . . .	170
Sarcoidosis . . . . .	172
Clinical Findings . . . . .	172
Diagnosis . . . . .	172
Treatment . . . . .	173
Antiphospholipid Syndrome . . . . .	173
Clinical Findings . . . . .	173
Diagnosis . . . . .	174
Treatment . . . . .	174
Systemic Sclerosis . . . . .	174
Clinical Findings . . . . .	175
Diagnosis . . . . .	176
Treatment . . . . .	176
Sjögren Syndrome . . . . .	176
Polymyositis and Dermatomyositis . . . . .	177
Polymyalgia Rheumatica . . . . .	178
Relapsing Polychondritis . . . . .	178
Vasculitis . . . . .	179
Large-Vessel Vasculitis . . . . .	179
Medium-Sized-Vessel Vasculitis . . . . .	181
Small-Vessel Vasculitis . . . . .	181
Variable-Vessel Vasculitis . . . . .	183
COVID-19 and Rheumatic Disease . . . . .	184
Medical Therapy for Rheumatic Disorders . . . . .	185
Corticosteroids . . . . .	185
Nonsteroidal Anti-inflammatory Drugs . . . . .	186
Disease-Modifying Antirheumatic Drugs . . . . .	187

<b>11</b>	<b>Geriatrics</b>	<b>193</b>
Highlights	193	
Introduction	193	
The Aging Eye: Physiologic Changes and Pathologic Findings	194	
Psychology of Aging	195	
Depression	195	
Alzheimer Disease and Dementia	197	
Special Topics	197	
Elder Abuse	197	
Osteoporosis	199	
Falls	200	
Perioperative Considerations in the Management of Older Adult Patients	201	
<b>12</b>	<b>Behavioral and Neurologic Disorders</b>	<b>203</b>
Highlights	203	
Introduction	203	
Behavioral Disorders	204	
Mood Disorders Associated With Medical Conditions	204	
Mood (Affective) Disorders	205	
Somatization, Anxiety, and Stress-Related Disorders	206	
Personality Disorders	208	
Schizophrenia	208	
Eating Disorders	209	
Substance Use Disorders	209	
Mandatory Reporting of Abuse and Neglect	210	
Pharmacologic Treatment of Psychiatric Disorders	210	
Antipsychotic Drugs	210	
Antianxiety and Hypnotic Drugs	212	
Neurologic Disorders	215	
Parkinson Disease	215	
Multiple Sclerosis	217	
Epilepsy	217	
Stroke	219	
Alzheimer Disease and Dementia	219	
Prion-Associated Neurologic Disorders	221	
Informed Consent in Patients With Behavioral or Neurologic Disorders	222	
<b>13</b>	<b>Preventive Medicine</b>	<b>223</b>
Highlights	223	
Screening Procedures	223	
Cardiovascular Diseases	224	
Cancer	225	
Infectious Diseases	232	
Immunization	233	
Hepatitis	234	

Influenza . . . . .	237
Varicella-Zoster . . . . .	237
Measles, Mumps, and Rubella . . . . .	238
Polio . . . . .	239
Tetanus, Diphtheria, and Pertussis . . . . .	239
Rotavirus . . . . .	240
Pneumococcal Pneumonia . . . . .	240
<i>Haemophilus influenzae</i> . . . . .	241
Meningococcus . . . . .	241
Human Papillomavirus . . . . .	242
Malaria . . . . .	242
COVID-19 (SARS-CoV-2) . . . . .	242
Travel Immunizations . . . . .	243
New and Future Vaccines. . . . .	244
<b>14 Cancer . . . . .</b>	<b>245</b>
Highlights . . . . .	245
Introduction . . . . .	245
Etiology . . . . .	246
Genetic and Environmental Factors . . . . .	246
Radiation . . . . .	246
Viruses . . . . .	246
Familial Cancers . . . . .	247
Staging . . . . .	248
Treatment . . . . .	248
Surgical Management . . . . .	248
Radiation Therapy . . . . .	248
Chemotherapy . . . . .	251
Angiogenesis Inhibitors . . . . .	252
Biologic Therapies . . . . .	252
<b>15 Infectious Diseases . . . . .</b>	<b>255</b>
Highlights . . . . .	255
General Immunology . . . . .	255
Bacterial Infections . . . . .	256
<i>Staphylococcus</i> . . . . .	256
<i>Streptococcus</i> . . . . .	257
<i>Clostridioides difficile</i> . . . . .	258
<i>Haemophilus influenzae</i> . . . . .	260
<i>Pseudomonas aeruginosa</i> . . . . .	260
<i>Borrelia burgdorferi</i> . . . . .	261
<i>Mycoplasma pneumoniae</i> . . . . .	262
<i>Neisseria</i> . . . . .	262
<i>Chlamydia trachomatis</i> . . . . .	263
<i>Treponema pallidum</i> . . . . .	264
Mycobacteria . . . . .	266
Fungal Infections . . . . .	267

Parasitic Infection . . . . .	268
<i>Toxoplasma</i> . . . . .	268
Viral Infections . . . . .	269
Herpesvirus . . . . .	269
COVID-19 (SARS-CoV-2) . . . . .	272
Influenza . . . . .	273
Hepatitis . . . . .	273
Human Papillomavirus . . . . .	274
Ebola Virus. . . . .	274
Zika Virus . . . . .	275
Human Immunodeficiency Virus . . . . .	276
Update on Antibiotics . . . . .	280
Antibacterial Agents. . . . .	280
Antifungal Agents. . . . .	287
Antiviral Agents . . . . .	288
<b>16 Perioperative Management in Ocular Surgery . . . . .</b>	<b>291</b>
Highlights . . . . .	291
Introduction . . . . .	291
Preoperative Assessment. . . . .	291
Children and Adolescents . . . . .	293
Management of Medical Conditions Associated	
With Increased Perioperative Risk . . . . .	294
Cardiovascular Disease . . . . .	294
Diabetes . . . . .	295
Respiratory Diseases. . . . .	295
Liver Disease . . . . .	296
Perioperative Medication Management . . . . .	296
Cardiac Medications. . . . .	296
Diabetes Medications . . . . .	298
Pulmonary Medications . . . . .	298
Perioperative Considerations . . . . .	298
Preoperative Fasting . . . . .	298
Latex Allergy . . . . .	299
Universal Protocol . . . . .	299
Intraoperative Considerations . . . . .	300
Systemic Anesthetic Agents. . . . .	300
Local Anesthetic Agents . . . . .	302
Malignant Hyperthermia. . . . .	303
Prevention of Intraoperative Fire . . . . .	305
<b>17 Medical Emergencies and Adverse Effects of</b>	
<b>Ophthalmic and Systemic Medications . . . . .</b>	<b>307</b>
Highlights . . . . .	307
Introduction . . . . .	307
Cardiopulmonary Arrest . . . . .	308
Syncope . . . . .	312

Hypoglycemia . . . . .	312
Shock . . . . .	313
Classification . . . . .	313
Assessment . . . . .	313
Treatment . . . . .	314
Anaphylaxis . . . . .	314
Seizures and Status Epilepticus . . . . .	316
Toxic Reactions to Local Anesthetic Agents and Other Drugs . . . . .	317
Opioid Overdose . . . . .	319
Adverse Effects of Ophthalmic and Systemic Medications . . . . .	320
Additional Materials and Resources . . . . .	325
Requesting Continuing Medical Education Credit . . . . .	327
Study Questions . . . . .	329
Answers . . . . .	337
Index . . . . .	343